Karlin Daniel 4
4 · Definium Therapeutics, Inc. · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Definium Therapeutics (DFTX) CMO Daniel Karlin Sells 8,018 Shares
What Happened
Daniel Karlin, Chief Medical Officer of Definium Therapeutics (DFTX), reported the sale of 8,018 common shares on March 25, 2026. The shares were sold at a weighted average price of $18.47 for total proceeds of approximately $148,092. This was a sale (disposition) to satisfy tax withholding obligations related to vested restricted stock units.
Key Details
- Transaction date: March 25, 2026. Filing date: March 26, 2026 (appears timely).
- Price: weighted average $18.47; individual sale prices ranged from $18.36 to $18.80.
- Shares sold: 8,018; total proceeds ≈ $148,092.
- Shares owned after the transaction: not specified in the filing.
- Notable footnotes:
- F1: Sale to satisfy withholding tax on vested RSUs via sell-to-cover elections under a Rule 10b5-1 plan (plan adopted June 14, 2022).
- F2: Reported price is weighted average; seller can provide breakdown of shares sold at each price upon request.
- F3: Filing notes an amount includes 1,586 shares acquired under the 2024 Employee Share Purchase Plan (ESPP).
Context
This was a routine sell-to-cover transaction tied to tax withholding for vested awards, executed under a pre-established 10b5-1 plan. Such transactions are common and generally reflect tax obligations rather than a directional view on the company’s stock.
Insider Transaction Report
Form 4
Karlin Daniel
Chief Medical Officer
Transactions
- Sale
Common Shares
[F1][F2][F3]2026-03-25$18.47/sh−8,018$148,092→ 413,317 total
Footnotes (3)
- [F1]Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022.
- [F2]The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan.
Signature
/s/Mark Sullivan, Attorney-in-Fact for Dan Karlin|2026-03-26